002001:SZSEZhejiang NHU Company Ltd. Analysis
Data as of 2026-05-24 - not real-time
CN¥31.59
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Zhejiang NHU is trading below its 20‑day simple moving average while still above the identified support level, suggesting a modest upside cushion. The RSI sits in the high‑30s, hinting at a slight oversold condition, and the MACD histogram remains negative, reinforcing a short‑term bearish bias. Fundamentally, the company delivers solid revenue growth, strong operating margins and a healthy cash position, with debt levels comfortably covered by cash. The price‑to‑earnings multiple is well below the industry average, and the discounted cash‑flow model indicates a fair value substantially higher than the current market price, pointing to an undervalued equity. Dividend sustainability looks robust given a payout ratio under one‑third and strong free cash flow generation.
The stock exhibits elevated 30‑day volatility and a decreasing volume trend, which adds execution risk, yet its beta near zero suggests limited market‑wide correlation. With a solid dividend yield, attractive valuation and resilient fundamentals, the stock presents a compelling entry point for investors comfortable with sector‑specific and geographic exposure.
The stock exhibits elevated 30‑day volatility and a decreasing volume trend, which adds execution risk, yet its beta near zero suggests limited market‑wide correlation. With a solid dividend yield, attractive valuation and resilient fundamentals, the stock presents a compelling entry point for investors comfortable with sector‑specific and geographic exposure.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 6/10
Key Factors
- Price near support with upside potential to resistance
- RSI indicating mild oversold condition
- Strong cash generation supporting dividend
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervaluation relative to peers and DCF fair value
- Sustained revenue growth and high operating margins
- Attractive dividend yield with low payout ratio
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Fundamental resilience and solid ROE
- Continued expansion in specialty pharma and nutrition segments
- Long‑term upside from valuation gap and stable cash flow
Key Metrics & Analysis
Financial Health
Revenue Growth15.70%
Profit Margin29.05%
P/E Ratio14.4
ROE20.44%
ROA10.65%
Debt/Equity21.31
P/B Ratio2.8
Op. Cash FlowCN¥8.9B
Free Cash FlowCN¥5.7B
Industry P/E27.6
Technical Analysis
TrendNeutral
RSI39.8
SupportCN¥30.60
ResistanceCN¥35.60
MA 20CN¥33.19
MA 50CN¥34.88
MA 200CN¥27.67
MACDBearish
VolumeDecreasing
Fear & Greed Index91.61
Valuation
Fair ValueCN¥47.32
Target PriceCN¥38.07
Upside/Downside20.52%
GradeUndervalued
TypeBlend
Dividend Yield3.17%
Risk Assessment
Beta-0.03
Volatility41.49%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.